85%Confidence
0Views
FDASource
2026-03-22Date
Summary
Harbin Jixianglong's recall of Semaglutide for compounding use reveals significant quality control failures in the rapidly growing weight loss drug market. The lack of proper validation before distribution creates safety concerns and may lead to increased regulatory scrutiny of compounded semaglutide products.
Actionable: Avoid sourcing compounded semaglutide from Harbin Jixianglong and verify validation documentation from all compounding suppliers.
AI Confidence: 85%
Data Points
firmHarbin Jixianglong Biotech Co., Ltd.
classificationClass II
statusOngoing
distributionNationwide within the United States
productSemaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-1
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now